Abstract: Medical Implant (100), comprising a microbial cellulose tube (1), comprising a wall (2) having an inner surface (3) and an outer surface (4), wherein the wall comprises several layers (5, 6, 7) of microbial cellulose, wherein said layers are concentric or substantially concentric to a longitudinal axis (L) of the tube, a stent (9) which placed inside of the microbial cellulose tube (1), wherein an outer surface (10) of the stent contacts the inner surface (3) of the microbial cellulose tube (1), and method for producing such implant. The implant can be covered with newly created bile duct epithelium, thereby creating a new bile duct from body cells. The implant can be removed after completion of creation of the new bile duct. So, the implant as suitable as a temporary implant. The implant can be used for surgery, such as surgery of gall bladder, bile duct and/or liver, e.g. gall bladder removal, hepatobiliary malignancy surgery or liver transplantation.

Abstract: Exemplary methods can be provided for the determination of a microbial pathogen. In addition, exemplary methods can be provided for the determination of a microbial pathogen and its anti-infective resistance. Further, an exemplary method can be provided for determining a bacterium and its antibiotic resistance. Systems and computer-accessible media can be provided for the determination of a microbial pathogen and its anti-infective resistance.

Abstract: The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 being selected independently of one another from hydrogen and alkoxy. The compounds of formula (I) as ligands are suitable for the production of radioactively labelled 68Ga, 64Cu, 67Ga, 111In or 99mTc complexes. The invention further relates to a method for producing the compounds of formula (I) and the radioactively labelled complexes and to the use of the radioactively labelled complexes in imaging methods, such as PET/CT, in particular of the liver.

Abstract: The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value.

Abstract: A method of producing a pluripotent stem cell is provided. The method is comprising contacting a non-pluripotent donor cell obtained from a mammalian donor with a compound characterized by general formulas (1) and (3). Furthermore, methods for inducing OCT4 and NANOG, increasing histone 3 lysine methylation and the maintenance of pluripotency are provided.

Abstract: The invention relates to a nucleic acid molecule for use in a method of treatment of cancer. The nucleic acid molecule comprises a sequence selected from SEQ ID NO 001 to SEQ ID NO 038. The nucleic acid molecules provided are not provided for the treatment of laryngeal cancer.

Abstract: The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H-L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).

Abstract: The invention relates to a nucleic acid molecule for use in a method of treatment of cancer. The nucleic acid molecule comprises a sequence selected from SEQ ID NO 001 to SEQ ID NO 038. The nucleic acid molecules provided are not provided for the treatment of laryngeal cancer.

Abstract: The invention relates to a method for inducing pluripotent stem cells, wherein a mammalian cell is contacted with a compound characterized by a general formula 1 wherein R1 is (CH2)mE, with E being CCH or CN and m being 0, 1, or 2, and R2 is selected from F, CI, Br, OR3 and R3, with R3 being selected from H, (CHyF2-y)n CHXF3-X, with n=0 or 1. The invention further relates to stem cells obtained by the method of the invention, and culture media comprising the compound of the invention.

Abstract: The invention relates to a method for inducing pluripotent stem cells, wherein a mammalian cell is contacted with a compound characterized by a general formula 1 wherein R1 is (CH2)mE, with E being CCH or CN and m being 0, 1, or 2, and R2 is selected from F, CI, Br, OR3 and R3, with R3 being selected from H, (CHyF2-y)n CHXF3-X, with n=0 or 1. The invention further relates to stem cells obtained by the method of the invention, and culture media comprising the compound of the invention.

Abstract: The present invention relates to an implant for bundling a plurality of tendons, particularly chordae tendineae, wherein a three-dimensionally curved element, revolves around a central axis at a radius with respect to the central axis and wherein said radius is larger at a first portion of said curved element than at a second portion of said curved element and wherein said curved element is designed to encompass said plurality of tendons and to bundle them, causing an effective shortening of the tendons along the central axis of the curved element.

Abstract: The invention relates to a method for acquiring data in order to determine organ function, in particular the liver or kidney function, comprising one or more polymethine fluorescent dyes having a fluorescence emission maximum, measured in ethanol, of less than or equal to 820 nm, and to the use of dyes as markers for acquiring data in order to determine the organ function. The invention further relates to a kit for determining an organ function with a marker dye, and to a device for acquiring data in the method.